Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“In the past decade, survival in patients with BRPC or LAPC has improved with the use of preoperative multi-agent chemo-therapeutic regimens (that is, FOLFIRINOX and gemcitabine plus nab-paclitaxel ) 11,12 .”
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · cited 3×
“In patients with BRPC or LAPC, an upfront surgical resection is considered suboptimal and is associated with poor survival 6–8 , even in patients receiving adjuvant chemotherapy 9,10 .”
Estimated Projection of US Cancer Incidence and Death to 2040
Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4708 · Cited by 1,339
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081 · cited 1×
“Its importance is illustrated by the fact that approximately 30% of patients with pancreatic cancer who die do not have metastases 256 .”
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943
Versteijne, E., van Dam, J. L., Suker, M., Janssen, Q. P., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02233 · Cited by 786
Self-citationNeoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377 · cited 1×
“…borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), mainly according to the presence and extent of tumour involvement with major visceral vasculature (that is, superior mesenteric artery, coeliac axis, hepatic artery and portomesenteric venous axis ) 4 .”
Self-citationPancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369 · cited 1×
“Molecular and genetic subtyping of pancreatic cancer is crucial for the development of personalized and targeted therapies 293,294 .”
Ecker, B. L., Court, C. M., Janssen, Q. P., Tao, A. J., D’Angelica, M. I., Drebin, J. A., Gonen, M., O’Reilly, E. M., Jarnagin, W. R., Wei, A. C., et al. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000212 · Cited by 13 · cited 1×
“For example, in a study of 196 patients with localized pancreatic cancer, Ecker et al. found that a driver mutation in SMAD4 was associated with disease progression during preoperative FOLFIRINOX 296 .”
Cited by
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Self-citation
Metadata
- Authors
- Stoop, T. F., Theijse, R. T., Seelen, L. W. F., Groot Koerkamp, B., van Eijck, C. H. J., Wolfgang, C. L., van Tienhoven, G., van Santvoort, H. C., Molenaar, I. Q., Wilmink, J. W., Del Chiaro, M., Katz, M. H. G., Hackert, T., Besselink, M. G., & International Collaborative Group on Locally Advanced Pancreatic Cancer
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2023-11-30
- Volume
- 21
- Issue
- 2
- Pages
- 101-124
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W4389195644
- Cited by
- 201
- References
- 10
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41575-023-00856-2
- The paper
- Stoop, T. F., Theijse, R. T., Seelen, L. W. F., Groot Koerkamp, B., van Eijck, C. H. J., Wolfgang, C. L., van Tienhoven, G., van Santvoort, H. C., Molenaar, I. Q., Wilmink, J. W., Del Chiaro, M., Katz, M. H. G., Hackert, T., Besselink, M. G., & International Collaborative Group on Locally Advanced Pancreatic Cancer. (2024). Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-023-00856-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.